Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.

BACKGROUND Isotretinoin (13-cis-retinoic acid) is a synthetic vitamin A derivative, or retinoid, widely used in the treatment of cystic acne. Preclinical and clinical studies of high-dose isotretinoin in patients with head and neck squamous cell cancer (HNSCC) have produced encouraging results. We conducted a phase III randomized trial of low-dose isotretinoin versus placebo in early-stage HNSCC patients to assess its effect on second primary tumor incidence and survival. METHODS We randomly assigned 1190 patients who had been treated for stage I or II HNSCC to receive either low-dose isotretinoin (30 mg/day) or placebo for 3 years. The patients were monitored for up to 4 more years. Survival was analyzed by the Kaplan-Meier method, and Cox proportional hazards models were used for multivariable survival analysis. All statistical tests were two-sided. RESULTS Isotretinoin did not statistically significantly reduce the rate of second primary tumors (hazard ratio [HR] = 1.06, 95% confidence interval [CI] = 0.83 to 1.35) or increase survival (HR = 1.03, 95% CI = 0.81 to 1.32) compared with placebo in patients with early-stage HNSCC. Current smokers had a higher rate of second primary tumors than that of never (HR = 1.64, 95% CI = 1.08 to 2.50) or former (HR = 1.32, 95% CI = 1.01 to 1.71) smokers. The hazard ratio of death from any cause for current smokers versus never smokers was 2.51 (95% CI = 1.54 to 4.10) and for current smokers versus former smokers was 1.60 (95% CI = 1.23 to 2.07). Major sites of second primary tumors (n = 261) included lung (31%), oral cavity (17%), larynx (8%), and pharynx (5%). CONCLUSIONS Low-dose isotretinoin was not effective in reducing the rate of second primary tumors or death or smoking-related disease. Smoking statistically significantly increased the rate of second primary tumors and death. Ongoing trials are testing higher doses of isotretinoin as part of combination bioadjuvant therapeutic methods for patients with locally advanced HNSCC.

[1]  S. Lippman,et al.  Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Bolla,et al.  Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. , 1994, European journal of cancer.

[3]  下山正徳.  National Cancer Institute-Common Toxicity Criteria , 1999 .

[4]  S. Lippman,et al.  Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. , 1994, Journal of the National Cancer Institute.

[5]  P. Rubin,et al.  Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. , 1989, International journal of radiation oncology, biology, physics.

[6]  F. Khuri,et al.  Retinoids in lung cancer: friend, foe, or fellow traveler? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[8]  F. Khuri,et al.  Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model , 2005, Clinical Cancer Research.

[9]  B. Vikram.  Changing patterns of failure in advanced head and neck cancer. , 1984, Archives of otolaryngology.

[10]  J. Grandis,et al.  Simultaneously Targeting Epidermal Growth Factor Receptor Tyrosine Kinase and Cyclooxygenase-2, an Efficient Approach to Inhibition of Squamous Cell Carcinoma of the Head and Neck , 2004, Clinical Cancer Research.

[11]  K R Hess,et al.  Hazard function estimators: a simulation study. , 1999, Statistics in medicine.

[12]  M. Sporn,et al.  Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). , 1976, Federation proceedings.

[13]  J. Califano,et al.  Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  Dan Liu,et al.  Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Edward S. Kim,et al.  The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  J. Califano,et al.  11:40 AM: A Genetic Progression Model for Head and Neck Cancer: Implications for Field Cancerization , 1996 .

[17]  A. Hagenbeek,et al.  Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. , 1995, Journal of the National Cancer Institute.

[18]  W. Hong,et al.  13-cis-retinoic acid in the treatment of oral leukoplakia. , 1986, The New England journal of medicine.

[19]  S. Silverman,et al.  Tobacco usage in patients with head and neck carcinomas: a follow-up study on habit changes and second primary oral/oropharyngeal cancers. , 1983, Journal of the American Dental Association.

[20]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[21]  P. Crosignani,et al.  Tobacco Smoking, Alcohol Drinking and Dietary Factors as Determinants of New Primaries among Male Laryngeal Cancer Patients: A Case-Cohort Study , 1996, Tumori.

[22]  N. Altorki,et al.  Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. , 2001, The Lancet. Oncology.

[23]  Edward S. Kim,et al.  Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. , 2005, Archives of otolaryngology--head & neck surgery.

[24]  Y. Shim,et al.  Promoter methylation of retinoic acid receptor beta 2 and the development of second primary lung cancers in non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Ettinger,et al.  Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. , 1997, Journal of the National Cancer Institute.

[26]  S. Lippman,et al.  Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. , 2001, Journal of the National Cancer Institute.

[27]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[28]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[29]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[30]  O. Dalesio,et al.  EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. , 2000, Journal of the National Cancer Institute.

[31]  R. Figlin,et al.  Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Warren.  Multiple primary malignant tumors. A survey of the literature and a statistical study , 1932 .

[33]  M. Spitz,et al.  Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. , 1989, International journal of radiation oncology, biology, physics.

[34]  M. Tucker,et al.  Smoking Cessation after Successful Treatment of Small-Cell Lung Cancer Is Associated with Fewer Smoking-related Second Primary Cancers , 1993, Annals of Internal Medicine.

[35]  M Buyse,et al.  Adjuvant treatment of stage I lung cancer with high-dose vitamin A. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Rudin,et al.  An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  L J Peters,et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. , 1990, The New England journal of medicine.